StemCell Therapy

KIRKLAND, QC, Sept. 15, 2020 /CNW/ - Merck Canada Inc., an affiliate of Merck & Co., Inc., known as MSD outside the United States and Canada, announced today that Health Canada has approved BRENZYS, a TNF-inhibitor, for four new indications:

BRENZYS is a type of protein called a tumour necrosis factor (TNF) blocker that blocks the action of a substance the body makes called TNF-alpha. TNF-alpha is made by the body's immune system.5 People with immune diseases like JIA, PsA and PsO have too much TNF-alpha in their bodies, which can cause inflammation and lead to painful, swollen joints and raise thick, red, scaly patches ("psoriatic skin lesions") that can appear anywhere on the body.6 It can reduce the amount of TNF in the body to normal levels, helping to treat joint damage and psoriatic skin conditions. 7

An estimated one million Canadians live with psoriasis,8 and between 10 and 30% of these patients will develop psoriatic arthritis.9 Plaque Psoriasis is an inflammatory disease that affects the skin and can cause psoriatic skin lesions that can appear anywhere on the body.10 About 80% to 90% of people with psoriasis have plaque psoriasis, the most common type of psoriasis.11 PsA is usually seen in patients with PsO and affects both the joints and the skin.12 JIA is an inflammatory disease that affects the joints in the body and is the most common type of arthritis in children under the age of 16.13 Approximately 10,000 children and teens live with arthritis in Canada.14

"Merck is committed to providing Canadians with more therapeutic choices for patients and their treaters," says AnnA Van Acker, President, Merck Canada. "BRENZYS adds to Merck's portfolio of treatments for dermatological and inflammatory immune diseases and can help improve quality of life for patients living with psoriasis, psoriatic arthritis or juvenile idiopathic arthritis, as well as rheumatoid arthritis and ankylosing spondylitis."

About BRENZYS

BRENZYS is a biosimilar biologic drug (biosimilar)15 and authorized based on its similarity to ENBREL, which is already approved for use for PsO, PsA and JIA in Canada.16 A biosimilar is a biologic drug that is highly similar to a biologic drug already authorized for sale.17 Biosimilars are assessed and approved by Health Canada against the same meticulous standards used to ensure the quality, efficacy and safety of all other biologic drugs.18 Biosimilars provide patients more treatment options to help manage their disease and symptoms.

In addition to its use for the treatment of JIA, PsO and PsA, BRENZYS was first approved by Health Canada in 2016 for the treatment of moderate-to-severe rheumatoid arthritis (RA) in adults and ankylosing spondylitis (AS).19 It is administered by an injection under the skin and should be used under the guidance and supervision of a physician.20

Clinical efficacy and safety studies have been conducted in patients with rheumatoid arthritis to demonstrate clinical comparability between BRENZYS and ENBREL. The extrapolation of these data to support uses of BRENZYS in ankylosing spondylitis is based on the demonstrated comparability, in terms of product quality, non-clinical, human pharmacokinetic and clinical characteristics. Randomized clinical trials have not been conducted to compare BRENZYS to Enbrel in patients with psoriatic arthritis, ankylosing spondylitis, plaque psoriasis, juvenile idiopathic arthritis and pediatric psoriasis.21

The most common expected adverse reactions with BRENZYS are infections, injection site reactions and headaches. It should not be administered to patients with or at risk of sepsis. BRENZYS contains a Boxed Warning to alert health care professionals and patients about an increased risk of serious infections including tuberculosis and infections caused by bacteria, viruses or fungi that have spread throughout their body. The Boxed Warning also notes that malignancies, sometimes fatal, have been reported in children and teenage patients who started using TNF-blocking agents, including etanercept, at less than 18 years of age.22

About Merck

For more than 125 years, Merck, known as MSD outside of the United States and Canada, has been inventing for life, bringing forward medicines and vaccines for many of the world's most challenging diseases in pursuit of our mission to save and improve lives. We demonstrate our commitment to patients and population health by increasing access to health care through far-reaching policies, programs and partnerships. Today, Merck continues to be at the forefront of research to prevent and treat diseases that threaten people and animals including cancer, infectious diseases such as HIV and Ebola and emerging animal diseases as we aspire to be the premier research-intensive biopharmaceutical company in the world.

In Canada, Merck markets a broad range of vaccines, pharmaceutical and animal health products and is one of the top R&D investors in Canada, with investments totaling $89 million in 2019 and more than $1.3 billion since 2000. Based in Kirkland, Qubec, Merck employs approximately 650 people across the country. For more information about our operations in Canada, visit http://www.merck.ca and connect with us on YouTube and Twitter @MerckCanada.

Forward-Looking Statement of Merck & Co., Inc., Kenilworth, N.J., USA

This news release of Merck & Co., Inc., Kenilworth, N.J., USA (the "company") includes "forward-looking statements" within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company's management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company's patents and other protections for innovative products; and the exposure to litigation, including patent litigation and/or regulatory actions.

The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company's 2017 Annual Report on Form 10-K and the company's other filings with the Securities and Exchange Commission (SEC) available at the SEC's Internet site (www.sec.gov).

Please see the product monograph for BRENZYS (etanercept injection) at:

https://www.merck.ca/static/pdf/BRENZYS-PM_E.pdf

References

1 BRENZYS Product Monograph. Merck & Co. Inc. August 19, 2020.

2 Psoriasis. Canadian Dermatology Foundation. 2020.

3 Psoriatic Arthritis. Arthritis Society. 2020. https://arthritis.ca/about-arthritis/arthritis-types-(a-z)/types/psoriatic-arthritis

4 BRENZYS Product Monograph. Merck & Co. Inc. August 19, 2020.

5 BRENZYS Product Monograph. Merck & Co. Inc. August 19, 2020.

6 BRENZYS Product Monograph. Merck & Co. Inc. August 19, 2020.

7 BRENZYS Product Monograph. Merck & Co. Inc. August 19, 2020.

8 Psoriasis. Canadian Dermatology Foundation. 2020.

9 Psoriatic Arthritis. Arthritis Society. 2020. https://arthritis.ca/about-arthritis/arthritis-types-(a-z)/types/psoriatic-arthritis

10 BRENZYS Product Monograph. Merck & Co. Inc. August 19, 2020.

11 Symptoms. Canadian Association of Psoriasis Patients. 2014. canadianpsoriasis.ca/index.php/en/psoriasis/81-english/psoriasis/94-symptoms#:~:text=About%2080%25%20to%2090%25%20of,with%20silvery%20scales%20on%20top

12 BRENZYS Product Monograph. Merck & Co. Inc. August 19, 2020.

13 https://www.mayoclinic.org/diseases-conditions/juvenile-idiopathic-arthritis/symptoms-causes/syc-20374082

14 6 facts about Juvenile Idiopathic Arthritis. Montreal Children's Hospital. 2020. https://www.thechildren.com/health-info/conditions-and-illnesses/6-facts-about-juvenile-idiopathic-arthritis

15 BRENZYS Product Monograph. Merck & Co. Inc. August 19, 2020.

16 BRENZYS Product Monograph. Merck & Co. Inc. August 19, 2020.

17 Biosimilar Biologic Drugs in Canada: Fact Sheet. Government of Canada. August 27, 2019.

18 Biosimilar Biologic Drugs in Canada: Fact Sheet. Government of Canada. August 27, 2019.

19 BRENZYS Product Monograph. Merck & Co. Inc. August 19, 2020.

20 BRENZYS Product Monograph. Merck & Co. Inc. August 19, 2020.

21 BRENZYS Product Monograph. Merck & Co. Inc. August 19, 2020.

22 BRENZYS Product Monograph. Merck & Co. Inc. August 19, 2020.

SOURCE Merck

Company Codes: NYSE:MRK

View original post here:
BRENZYS (etanercept injection) now indicated for the Treatment of Plaque Psoriasis, Psoriatic Arthritis and Juvenile Idiopathic Arthritis - BioSpace

Theres no right way to practice self-care. It looks different for all of usultimately, good self-care consists of whatever helps you feel cared for. That's true for psoriatic arthritis self-care tips too. For people with psoriatic arthritis, an autoimmune condition that causes psoriasis symptoms plus issues like joint pain, stiffness, and swelling, self-care can be a huge help in managing the condition.

For people with arthritis, every day needs to be a bit of a self-care day, because you have to think of yourself before you think of anything else, Tanya G., 42, who was diagnosed 11 years ago but has had symptoms of psoriatic arthritis most of her life, tells SELF. Focusing on little things that can make your life easierlike having the right tools at your desk, or a talk-to-text app that you can use to email when your hands are flaredis self-care. Learning how to take things slowly and listening to your body is also self-care, says Annelyse A., 25, who creates artwork advocating for chronic illness on her Instagram account, Resting Itch Face. Surrounding yourself with people who care and support you? Also self-care.

Self-care simply boils down to taking care of yourself, says Tanya, sometimes in the most basic ways, and on an ongoing basis: Self-care is an everyday thing.

Here, Tanya, Annelyse, and Nitika C., 39, founder and CEO of Chronicon, a platform dedicated to elevating the lives of people with chronic illness, share the self-care practices and tips that have helped them live better with psoriatic arthritis.

You have to know what self-care means for you, says Tanya. For me, that means being prepared for bad days. Bad days will happen; theyre not going to magically go away. So what is going to be in my house that is going to support me on a bad day? For Tanya, this means having a few things on hand: bath bombs, a good book on her Kindle, and medication she can use during a serious flare. It means thinking ahead and doing laundry on a good day so her compression socks are clean and ready when she needs them. And, of course, it also means having her favorite comfort foods, like chocolate, on hand.

When I was really at my sickest in my 20s, I think the biggest thing that helped me was mindfulness, Nitika tells SELF. I didnt grow up knowing about it, but it really changed me. It made me feel like I could really help myself feel better on the inside, which I saw helped how I was feeling on the outside. Nitika says she noticed her stress levels go down when she learned how to stay present instead of letting the pain take over. Tanya also meditatesshe swears by the Calm app, specifically a training program the app has for pain management. I do it probably at least once a month to remember the steps for how to breathe through pain, she says.

While that laughter is the best medicine doesnt necessarily apply when it comes to chronic pain, it can still make a difference in how youre coping. Ive always known that friends and laughter were incredibly important, Nikita says. When she was younger and unable to get out of the house easily, she would call a friend to just talk. Not about psoriatic arthritis or the pain she was in, but just 20-something things like a cute guy or a weird dream or something that happened on a TV show. I remember that being so helpful. And even in times when that wasn't enough because maybe I was in so much pain or had a really big flare-up, I started getting into the habit of looking at funny videos online, like Carpool Karaoke, she adds. Its stupid and fun and makes me so happy, and its free.

For Tanya, self-care means making sure to surround herself with people who know that she may have to cancel plans and wont judge her or get angry at her for it. On the flip side, that also means distancing herself from people who just dont get itor rather, those who dont even attempt to understand. There are some people who don't get it who want to get it and say hurtful things because they just don't get it but want to be there for you. And then there are people who just think youre faking, and those are the people you have to distance yourself from, Tanya says.

Go here to read the rest:
9 Psoriatic Arthritis Self-Care Tips for Anyone With the Condition - Self

Arthritis is a common condition among dogs. It causes a lot of pain, and no pet parent wants their cuddle buddy to suffer! Read on to know how you can help your pooch cope with arthritis and its symptoms.

Arthritis in dogs can cause pain in the joints and affect dogs as they age. The most common type of arthritis that affects dogs is osteoarthritis, which usually affects seniors and large breeds. It is the inflammation of the joints caused by the deterioration of cartilage. Common symptoms of arthritis include limping, difficulty in moving, spinal issues, irritability, and tiredness. Some of the most common breeds that get affected by the problem include Labradors, Retrievers, German Shephard and Rottweilers.

Watching your furry friend suffering will definitely make you upset, and you might look for ways to curb the disease or decrease the pain. Well, there is no cure for the disease, but there are ways that can help to improve its symptoms. As a pet parent, you must help your canine to cope with the painful condition.

1- Arthritis is a common condition that affects overweight dogs. Helping them lose weight might decrease the pain and improve their symptoms.

2- Make them do gentle, controlled and low impact exercises that will keep them moving. It will help relieve the pain.

3-You can also invest in ramps to help your dog climb up the stairs, on the bed, stairs, or cars.

4-Regular massage will also help your pooch feel better. It will improve circulation, help them relax, lower blood pressure and reduce stress. You can gently massage your dogs joints, or seek professional help.

5- Invest in an orthopaedic dog bed that will support your quadrupeds joints and bones and help them relax.

6- Heating pads are another option that can help provide some relief. It will promote muscle relaxation, stimulate acupuncture points, and heal injuries.

ALSO READ:Want to know about your personality? Your pets can tell it all

x Your comment has been submitted to the moderation queue

Here is the original post:
Arthritis in Dogs: Heres how to help your canine cope with it - PINKVILLA

In her weekly column, Bradford West Gwillimbury licensed nutritionist Nonie De Long shares a few herbs you need in your medicine cabinet if you live with arthritis

Dear Nutritionist,

I suffer from arthritis and have to have a lot of medication for pain. I take daily NSAIDs and Im worried. I get horrible constipation and stomach pain and I notice the joint pain has started to get resistant. Ive had to go higher in my dose, which worries me. My rheumatoid arthritis started fiveyears ago. I was told it only gets progressively worse. I know theres no known cure but would you know of any safe and natural treatment that can help with the pain so I could reduce the amount of NSAIDs I take? Thank you for your column!

Thank you!Melaena from Barrie

Dear Malaena,

I love these difficult questions, keep them coming!

You are going to be on cloud 9, Malaena, because I know holistic therapies that both help with the pain of RH arthritis and ones that help manage it long-term. This is because I used to suffer from it. But not anymore.

You see, when I was 19 I was diagnosed with it. I had gotten mononucleosis from working at a cafe and handling all the dishware. When my immune system was taken out with mono I developed painful swelling in all my joints. I mean every joint - even my toes! My knees were at least 3x their normal size! I was at first diagnosed with water on the knee then had tests for rheumatoid factor (RF) and was diagnosed with migratory rheumatoid arthritis. They said it was migratory because after the initial flare up it moved around from joint to joint, often taking out several at once.

I was so ceased up I had to manually unlock my joints after sleeping because they would lock up in the position I had been in. It was excruciating. Ladies, think of the pain of labour and multiply that by 10! Its unbelievable how painful it is! Once I got moving I had to crawl to the bath - probably 3x a day - to soak in hot water. It was the only thing that gave me any relief.

All I could do was eat boiled noodles, drink hot chocolate, crush tylenol 3, bathe, and sleep. I moved like a zombie and a friend who saw me during that time commented that I looked like I had aged 30 years.

Fast forward to today and I rarely have a flare up and know exactly how to treat it if I do. But the solution came in increments over the years. Let me explain.

First, let me back up. During the flare up I had a manual car and couldnt drive because my knees couldnt handle it. This was before cell phones so I didnt have one of those either. And I had lost my job so I didnt have a landline either. I lived in the country and my then partner left. So I eventually ran out of food and hot chocolate. When I did I was forced to water fast. I now know water fasting is extremely beneficial for overcoming inflammation but I didnt know that then. I just knew that spontaneously started to get better. Within threedays of no food (toxins) I was feeling much much improved. Enough to drive and stop the T3. Once I did that, I never got so bad again.

But every year when I returned to school and rather frequently after parties the RA would flare up - sometimes for days and sometimes for months. It mostly affected my knees but also my elbows and shoulders and every time I had to wake to ceased joints I would get that familiar terror... wondering if it was coming back again. I lived in fear. Doctors and specialists could not explain the coming and going symptoms.

Then my stepmother made a discovery.

My father had had a triple bypass and had to switch to decaf for his recovery. Because of that she switched, too. She reported to me that her arthritis was much improved. Did I want to try it for mine? Well, it was easy enough to do so I switched to decaf all the time. Immediately I got about an 80 per centimprovement. So I ditched the caffeine altogether for a couple weeks and the RA went away entirely. I was flabbergasted. Everything started to make sense.

When I returned to school or went to functions I invariably drank coffee that I would not drink at home. Or eat a little chocolate something. I didnt have these in my home. I drank decaf at home because I knew the caffeine made me jittery. So when I drank regular coffee at school or functions I would get a flare up. I also realized why it got so bad with my migraines. My migraine medicine has caffeine in it. Guess what else does? T3s.

I had been living on hot chocolate and T3s when I had my worst flare up!

Today I have to be careful how much caffeine I have. But it took me years to be able to tolerate it at all. I had to work on my liver and remove low grade food intolerances from my diet. Still, if I overdo caffeine, dairy, and wheat I am down for a couple days. You could say those are my kryptonite.

Every person Ive treated for RA has serious underlying food intolerances and is sensitive to some degree to alcohol and caffeine. They usually also have some issues with their blood and digestion. Aside from telling you to switch to swiss water decaf and throw out the teas and chocolate immediately, I want you to avoid all alcohol and talk to your doctor about replacing any medications that have caffeine for a trial to see if it benefits you. I suggest you get food intolerance testing by a professional and figure out which foods trigger you. This is essential in the long run.

Next I suggest a few herbs to help with pain relief. NSAIDs are particularly damaging not only to the lining of the stomach and digestive system but to the gut biome, and this causes an increase in inflammation over time! That is not what we want.

Turmeric and the curcumin from it are both extremely beneficial in helping joint pain. They thin the blood, though, so a licensed physician needs to supervise use if you are taking blood thinners. The good news is it can work just like low dose aspirin without the side effects. But again, do not make changes without talking to a doctor to oversee this if you take meds for your blood. You can get this supplement in capsule form and you can add powdered turmeric to your food. Most potent may be the liposomal form, but it would need to be consumed with food. You can also use the root, which looks like a bright orangey yellow ginger - to fresh juices for added benefit.

The reason NSAIDs damage the stomach lining is they down regulate prostaglandins - of which some cause pain and some protect against pain and protect tissues like the stomach lining. We can effectively increase the beneficial prostaglandins by adding quality krill or cod liver or omega 3 fish oil into the diet as a supplement in therapeutic quantities (again taken with meals) and adding sardines and salmon (with skin and bones) into the weekly diet. You would be amazed how many cool recipes there are for sardines and canned salmon on the internet. Do a search and try something new!

In addition, using herbs to help your liver work better helps address this issue at the root. I use milk thistle, dandelion, and alpha lipoic acid in high doses with custom herbal tinctures for clients with these issues. Professional supervision is best for any high dose of supplements for any length of time.

I also recommend a liquid diet to take strain off of the digestive system and ensure all nutrients are being absorbed optimally until the bodys inflammation is under control. Bone broth is particularly soothing to a weak digestive system. I also recommend smoothies with quality protein and collagen peptides to help nourish without producing inflammation. This has been very effective in a number of clients in reducing pain.

Another remedy for pain that is incredible and simple is capsaicin cream. Its made from the active ingredient in chilli peppers and helps reduce the transmission of pain signals in the nerves. It can be really helpful for rubbing on the site of pain and is very safe - as long as you use gloves to apply it and dont rub your eyes after!

Lastly, homeopathics that fit your specific situation are essential if you want to turn the problem around permanently. But homeopathic remedies applied without knowledgeable dietary intervention do not produce the same results in clients, in my experience. Nutrition is the foundation of the inflammatory response in the body.

I hope this helps your pain, Malaena, and invite you to reach out to address the arthritis more deeply together.

As always, if you have your own health/nutrition questions, dont hesitate to send me an email at nonienutritionista@gmail.com. Readers can find out more about my work and sign up for my newsletter at hopenotdope.ca.

Namaste!Nonie Nutritionista

See the original post here:
If you have arthritis, here are some ideas that could help - BradfordToday

Patients with lifelong psoriatic arthritis are required to undergo treatments for prolonged periods of time. Furthermore, the higher burden of co-morbidities in the elderly population has the potential of complicating treatment course.

A new study presented at the Clinical Congress of Rheumatology (CRR) East 2020 demonstrated that treatment with ustekinumab resulted in similar efficacy and safety profiles for both age populations.

Ustekinumab specifically targets the shared p40 subunit of Interleukin (IL)-12 and IL-23. The treatment is indicated for adult patients with active psoriatic arthritis.

A team led by Elke Theander, MD, PhD, Medical Advisor of Rheumatology, Janssen Pharmaceutica, conducted a post-hoc analysis of the PsABio Study with a specific focus on comparing treatment outcomes in patients aged <60 (n = 336) and 60 (n = 102) years.

The investigators in the original study had recruited 930 patients and assigned about half to receive ustekinumab as 1st, 2nd, or 3rd line of treatment.

They then measured effectiveness using components of the American College of Rheumatology (ACR) response criteria in addition to the clinical disease activity index for psoriatic arthritis (cDAPSA) and minimal disease activity (MDA).

In the post-hoc analysis, reported mean age within the older population was 67.3 years; in the younger population, mean age was 46.1.

As noted by Theander and colleagues, both groups had similar baseline characteristics.

However, the older population had a longer psoriatic arthritis disease duration as well as a higher proportion with a history of cardiovascular disease and corticosteroid use.

Following 6 months of treatment with ustekinumab, the two subpopulations reported similar changes from baseline in components of the ACR response criteria.

Additionally, 52.2% of patients <60 years achieved cDAPSA low disease or remissioncompared with 42.9% in the 60 years group.

Mean cDAPSA was -14.4 (95% CI, -16.5 to -12.2) for the younger patients and -12.6 (95% CI, -16.1 to -9.1) for the older patients.

Furthermore, 30.0% and 20.3% of the younger and older populations, respectively, achieved MDA.

Up to 18.5% of patients <60 years experienced 1 adverse eventsversus 20.0% percent in those 60 years.

Other safety measures1 serious adverse events and withdrawal of treatment due to adverse eventswere similarly comparable between the groups.

In a real-world setting, no clinically meaningful differences were observed in the effectiveness and safety of ustekinumab treatment in PsA patients 60 years or older compared with those younger than 60, Theander and team wrote.

The study, "Effectiveness and Safety of Ustekinumab in Patients with Psoriatic Arthritis in a Real-world, Multicenter Study: A Post-hoc Analysis Comparing Elderly to Younger Patients," was presented at CCR East 2020.

Read the original here:
Ustekinumab Safe and Efficacious in Young and Elderly Patients with Psoriatic Arthritis - MD Magazine

Arthritis is a general term for more than 100 types of joint pain or joint disease. However, osteoarthritis and rheumatoid arthritis are the two most common types of arthritis. Common arthritis joint symptoms include swelling, pain, stiffness and decreased range of motion.

These symptoms can greatly diminish a person's quality of life by making even simple tasks trying.

Unfortunately, there's no cure for arthritis, but there are many treatments that can help to alleviate symptoms.

Research has found a number of natural remedies that reduce the inflammation associated with arthritis.

Stinging nettle, which can be processed into supplements, dried, freeze-dried or cooked, appears to boast anti-inflammatory properties.

READ MORE:Best supplements for arthritis: The top three supplements to help ease painful joints

Stinging nettle packs a variety of compounds that may reduce inflammation, research suggests.

In animal and test-tube studies, stinging nettle reduced levels of multiple inflammatory hormones by interfering with their production.

In human studies, applying a stinging nettle cream or consuming stinging nettle products appeared to relieve inflammatory conditions, such as arthritis.

For instance, in one 27-person study, applying a stinging nettle cream onto arthritis-affected areas significantly reduced pain, compared to placebo treatment.

DON'T MISSBed bugs: The three different warning smells indicating you may have an infestation[INSIGHT]Hair loss treatment - Dr Sara explains the best type of shampoo to stimulate hair growth[ADVICE]Bowel cancer: Smelly warning sign which could indicate early diagnosis of deadly condition[INSIGHT]

In another study, taking a supplement that contained stinging nettle extract significantly reduced arthritis pain.

Additionally, participants felt they could reduce their dose of anti-inflammatory pain relievers because of this capsule.

If your arthritis is painful, you may not feel like exercising. However, being active can help reduce and prevent pain.

According to the NHS, regular exercise can also:

A growing body of research supports the benefit of aerobic and strengthening exercise in alleviating arthritis, according to a literature review.

It suggested that the intensity level of the aerobic exercise should be moderate to hard and exercise be performed three times weekly for a duration of 30 to 60 minutes.

Any type of exercise which makes you breathe deeper and faster can be aerobic.

Examples of low-impact aerobic exercises that are easier on your joints include walking, bicycling and swimming.

Exercise also aids weight loss, which is crucial for managing arthritis symptoms.

The NHS explains: "Too much weight places excess pressure on the joints in your hips, knees, ankles and feet, leading to increased pain and mobility problems."

To help you maintain a healthy weight and alleviate your arthritis symptoms, it's very important to eat a healthy, balanced diet, says the health body.

Your diet should consist of a variety of foods from all five food groups.

These are:

See the rest here:
Arthritis treatment: Apply this herbal cream to significantly reduce pain - Express

A new study presented at the 14th Annual North American Young Rheumatology Investigator Forum (NYRIF 2020) found an association between seropositive rheumatoid factor (RF) or the presence of anti-cyclic citrullinated antibodies (ACPA) and an increased prevalence of interstitial lung disease (ILD) among patients with rheumatoid arthritis.

The retrospective case-control review, led by Samarth Mathapathi, MD, Resident at Scripps Green Hospital, examined various combinations of RF and ACPA serotypes among patients in order to determine associations with ILD prevalence.Furthermore, they compared selected outcomes to see whether seropositivity can help predict the course of rheumatoid arthritis ILD.

Mathapathi and team assessed a total of 2084 adult patients with rheumatoid arthritis with and without ILD. Of the total, 82 had ILD, and 2002 did not.

They excluded patients with other rheumatologic or pulmonary conditions.

Furthermore, the team defined RF positive (RF (+)) as RF >15 IU/mL, and ACPA positive (ACPA (+)) as ACPA >6 IU/mL.

In their analysis, patients were divided into groups according to RF and ACPA status. Then they compared ILD prevalence, pulmonary function tests, progression of CT/chest X-ray, average pulmonary artery pressures, home oxygen dependency, all-cause mortality, and hospitalization for respiratory failures rates among the cohorts.

Thus, the investigators noted that prevalence of ILD was 6.3% and 5.2% in the RF (+) / ACPA (+) and RF (+) / ACPA (-) groups, respectively (P = .534).

Prevalence was 3.9% in the RF (-) / ACPA (+) group and 1.3% in the RF (-) / ACPA (-) group (P < 0.05).

Furthermore, the mean titers of ACPA and RF in all ILD cohorts were 397 IU/mL and 484 IU/mL, respectively.

For those without ILD, means titers were 235 IU/mL for RF and 250 IU/mL for ACPA.

When compared across all the ILD groups, the outcomes among all other aforementioned measures were not significantly difference (P > .05).

The only notable exception was progression on imagingwhich was significant only in the RF (+) / ACPA (-) group. Thus, the investigators believed that this finding suggests a potential difference in disease course or other confounding underlying conditions.

Positive and higher titers of ACPA or RF may help predict development of RA-ILD but may not help prognosticate disease course, they concluded.

They acknowledged that larger and prospective studies would be necessary to confirm and validate their findings.

Concomitant rheumatoid arthritis and ILD has a varying prevalence, ranging from 3.2-6.0 cases per 100,000. The median survival rate is 7.8 years.Notable risk factors include age, female sex, and severity of rheumatoid arthritis.

The study, Comparison of Selected Outcomes in Seropositive vs. Seronegative Rheumatoid Arthritis-Associated Interstitial Lung Disease (RA-ILD), was presented at NYRIF 2020.

Read the rest here:
Seropositive Antibodies Linked with Prevalence of Rheumatoid Arthritis-Associated ILD. - MD Magazine

'For people with arthritis, it is all about accessibility and comfort,' says Michael Kulava, who lives with rheumatoid arthritis himself and will be taking part in New York Fashion Week

A world-class fashion designer,who now lives locally,is helping those suffering from a painful ailment by bringing awareness to the New York stage.

Michael Kuluva is a fashion designer who has travelled the world and now calls Barrie home. Kuvula also lives with rheumatoid arthritis, but he doesnt let it define or hinder him. The autoimmune disorder primarily affects joints and can be very painful, something Kuvula knows all too well.

I was diagnosed 12 years ago and I didnt really know what to expect, the 37-year-old said. It has been a tough road at times, but you learn to live with and deal with all that it comes with.

Kuluva has even taken his passion for fashion design and used it to not only bring awareness to arthritis, but also help those who suffer from it.

The Newest Normal virtual event will premiereduring New York Fashion Week on Sept. 16 at 8 p.m. on the Virtual Fashion Show website and on YouTube.

Kuvula needed to film his show with models and a crew, but during COVID timesthat was tricky.

I was supposed to get back to the States, but obviously international travel couldnt happen. We filmed it here in downtown Barrie with local models and very few people in order to follow COVID protocol,Kuvula said. It was a very unique event and makes you realize that when you want to accomplish your goals, you can find a way.

Kuluva has been a part of New York Fashion Week for the last 11 seasons and will be a prominent figure in the 2020 edition. This years collection from the designer is titled Tumbler and Tipsy and includes clothes that are arthritis-friendly.

For people with arthritis, it is all about accessibility and comfort. Buttons are no good, so Ive altered that a bit with zippers, straps and other easy-to-wear items,Kuluva said. We know how to live with the discomfort, but we shouldn't have to let it stop us from getting out there and wearing what we want.

This years Kuluva collection is being described as deliberately sassy and also includes hand-painted, glow-in-the-dark details thoughtfully placed to emphasize where people living with arthritis experience pain.

It is fun, obviously, but it also highlights the pains that we experience that many dont know we have. Glowing over the joints and other spots that experience pain is a justa way to bring awareness to arthritis, said Kuluva.

Kuluva has travelled all over the world and in what he called, the different realms of New York, Los Angelesand Europe.

For the last four years, he has called Barrie home with his partner and enjoys everything about the region, even dedicating a line of clothes to it.

Barrie is wonderfuland the whole area is beautiful. Id obviously been to Toronto before and being in Barrie is even so close to Muskoka, said Kuluva. I have a Tipsy line of clothes for Muskoka, Toronto and the Canadian feel.

For more on Kuvula and his work, click here to see his website.

Read the original post:
Local fashion designer unveiling new line of arthritis-friendly clothing - OrilliaMatters

This is the time of year when fresh produce is at its peak.

The farmers markets and grocery stores are an abundance of natures glory. Fruit is literally falling off the trees. Home gardens are bursting with joyful rewards of months of labor and love.

Its also a time of year when I see more arthritis patients joints seem to be acting up or more troublesome. Folks often attribute this to using their hands more in the garden, painting projects, etc. Sometimes over-work is absolutely the culprit. And sometimes it can be tied back to eating an abundance of garden booty salsa, green chile, gazpacho or tomatoes warm from the vine.

What do these foods have in common? They are part of the nightshade, or Solanaceae, family. This group of foods is high in glycoalkaloids, especially solanine. It is theorized that these glycoalkaloids can be pro-inflammatory in some people and could be a contributor to arthritic pain. This class of foods includes potatoes, tomatoes, all peppers, eggplant, tomatillos, paprika and cayenne. The nightshade family does not include sweet potatoes, yams or black pepper.

The easiest way to know if these are foods that are causing more pain in your joints is simply to cut them out for 3-4 weeks completely. This is one of the hardest recommendations I make in my practice because this time of year the nightshade foods are so delicious! Veggies in the nightshade family are also high in nutrients, especially vitamins C and A. However, both osteoarthritis and rheumatoid arthritis can be debilitating and neither have great Western medical interventions available. The treatments that are offered often carry their own concerning side effects.

Adjusting your diet to see if certain foods are impacting you is a great way to take your health into your own hands. It doesnt require any testing and is free! There are a couple simple guidelines that can help this be more successful for you. The first is to be diligent and not cheat. You must strictly eliminate the foods in question for at least 3 weeks no exception, otherwise youll never know for sure. Choose a time frame that works for you having start and end dates are essential. (It helps to know theres a light at the end of the tunnel!) Look at your calendar and plan for what you might do if you have events scheduled. Take some time to clear out the foods youre avoiding from your kitchen and think about what you might eat instead. For example, if you love pasta, pesto would be a great alternative to red sauce. Take time each day to record the severity of your symptoms. It is impossible to remember what your pain was like 2 weeks ago and can be helpful to notice if it dropped from a 7 to a 4, as opposed to saying it still hurts.

Finally, connect with your deeper why. If you didnt have joint pain, what would that create in your life? Write that down and keep it on your fridge, in your car and your bathroom to keep you inspired about whats really important.

Remember, not everyone will have this reaction to nightshades. And if you notice that they impact you, play with those foods in moderation. You can also just eat one of the foods (like peppers) and see how that feels in your body it might be that a particular food within the group is more of an issue. Either way, youll be more connected to you.

Nicola Dehlinger is a naturopathic doctor at Pura Vida Natural Healthcare in Durango. She can be reached at 426-1684 or http://www.puravidahealthcare.com.

Continue reading here:
Nightshades and arthritis are often connected - The Durango Herald

Maintaining a healthy weight plays an important role in managing psoriatic arthritis. Obesity causes low-grade inflammation, as fat tissue churns out inflammatory proteins, including cytokines, chemokines, and adipokines. Being overweight or obese has been linked to an increased risk of developing psoriatic arthritis, an inflammatory condition, and making it more difficult to manage.

Excess weight puts more pressure on your joints, which can lead to injury and inflammation. Whats more, excess weight can interfere with medications that treat psoriatic arthritis, so they dont work as well. A review published in May 2018 in the journal PLoS ONE found that obesity was linked to a 60 percent greater chance that a class of biologic drugs commonly used to treat psoriatic arthritis, called tumor necrosis factor (TNF) inhibitors, wouldnt work.

The link between obesity and psoriatic arthritis is very complex and not adequately understood, says John Davis, III, MD, a clinical rheumatologist who specializes in psoriatic arthritis at Mayo Clinic in Rochester, Minnesota. We believe that [obesity] drives inflammation, providing the link to the joint disease.

Psoriatic arthritis is also linked to other health conditions, such as heart disease, diabetes, and metabolic syndrome. For all of these, Losing weight and maintaining weight in a healthy range is important, says Melissa Ann Prest, DCN, RDN, a spokesperson for the Academy of Nutrition and Dietetics.

The good news: Weight loss has been linked to an improvement in psoriatic arthritis symptoms, including painful, swollen joints and fatigue. Its probably reducing the inflammatory burden, says Dr. Davis.

American College of Rheumatology and National Psoriasis Foundation (NPF) guidelines, published in November 2018 in the journal Arthritis & Rheumatology, recommend weight loss for all obese people who have psoriatic arthritis to help improve their response to medication. Losing weight helps psoriatic arthritis symptoms in other ways, as well, explains Rajat Bhatt, MD, a rheumatologist with Memorial Hermann Health System in Texas. It decreases inflammation and stress on the joints and lowers uric acid levels linked to gout another joint condition common in people who have psoriatic arthritis.

And weight loss doesnt have to be major. Research has found that overweight and obese people with psoriatic arthritis who lost just 5 percent of their body weight were more likely to have minimal disease activity.

Although psoriatic arthritis symptoms such as fatigue and stiff, achy joints can make it more challenging to move, its possible to drop extra pounds with the right strategies and support. Here are a some tips to help you lose weight and improve your symptoms.

Daviss number one tip for weight loss in people who have psoriatic arthritis is to eliminate added sugars. They provide extra calories that dont benefit your body and can increase chronic inflammation, upping your risk of related conditions, such as obesity and diabetes.

Another reason to cut back on sugar: A review published in April 2020 in the journal Rheumatology and Therapy found that people who have psoriatic arthritis are significantly more likely to have type 2 diabetes than the population at large, possibly because inflammation of the skin and joints may affect glucose metabolism. Davis recommends limiting simple sugars and carbohydrates in your diet. Sugar hides in processed foods, cereal, yogurts, and juices, he says.

The NPF also recommends cutting out the following:

Foods from these sources are typically going to be higher in calories and trans fat, which can contribute to weight gain and inflammation, says Dr. Prest.Because cutting out these foods helps reduce inflammation, which worsens psoriatic arthritis, it may also help reduce psoriatic arthritis symptoms, explains Dr. Bhatt.

Research suggests that eating lots of fruits and vegetables can help you lose weight by keeping you full and satisfied on fewer calories, according to the Centers for Disease Control and Prevention (CDC). People should definitely eat more fruits and veggies, adds Davis.

A plant-based diet can also help decrease inflammation levels, which may reduce psoriatic arthritis symptoms, adds Bhatt. He specifically recommends the Mediterranean diet, which is rich in anti-inflammatory omega-3 fatty acids.

Dietary guidelines from the medical board of the NPF published in August 2018 in JAMA Dermatology, also recommend a Mediterranean diet, consisting of at least:

Make vegetables the star of your meal by filling half of your plate with non-starchy vegetables, and go with a serving of fruit or a serving of a vegetable for snacks, says Prest.

Its easy to confuse thirst for hunger, according to the NPF. So be sure to drink enough water to help with your weight loss efforts. About eight 8-ounce glasses per day is a good goal, according to the Mayo Clinic. Youll know youre hydrated if your urine is clear to light yellow.

Physical activity helps reduce inflammation and pain. Weight loss guidelines from the CDC recommend at least 150 minutes of moderate physical activity per week. Exercise is great for your overall health and to break through those weight loss plateaus, says Prest.

Staying physically active is especially important for people who have psoriatic arthritis, as metabolic syndrome has been linked to psoriatic arthritis disease activity and medication effectiveness, says Bhatt. Exercise can help you tackle metabolic syndrome by reducing inflammation and improving muscular metabolism. And thats not all. Exercise can increase range of motion in the joints and maintain joint flexibility and muscle strength, says Bhatt. Physical activity also increases pain tolerance, helping psoriatic arthritis symptoms feel less debilitating, and decreases uric acid, which reduces joint pain in people who also have gout, he adds.

If youre experiencing a lot of joint pain in your lower extremities, Bhatt recommends swimming a few laps. Swimming is a good low-impact activity for those who have access to a pool and enjoy it, says Davis.

Walking is a great exercise for people with psoriatic arthritis to lose weight, says Davis. Maintaining daily activity and step counts [helps] to increase metabolism, he says. When combined with dietary changes, walking supports weight loss, according to the Mayo Clinic, and is especially important for weight loss maintenance.

A study published in December 2018 in the journal BioMed Research International suggests that weight-bearing aerobic exercises, such as walking, may help reduce the risk of bone loss. Thats important, as another study, published in July 2020 in Annals of the Rheumatic Diseases, suggests that psoriatic arthritis treatments may increase the risk of osteoporosis.

If you need extra motivation, use a fitness tracker to track your steps. Set small, manageable goals that slightly challenge you. And listen to your body: Its natural to feel a bit sore or tired the next day, but take it easy if you feel pain.

Once your routine is no longer challenging, consider increasing the intensity. The body always has to be challenged. Choose something you like, so you can stick to a long-term plan, says Bhatt.

Resistance training, which includes weight lifting and body weight exercises, such as squats, can help with both weight loss and overall fitness. One small study published in February 2018 in the journal Clinical Rheumatology found that people with psoriatic arthritis who did resistance training twice a week for 12 weeks reduced their disease activity and pain and improved their quality of life.

Whats more, building muscle helps with weight loss. Thats because muscle burns more calories than fat does, even at rest, according to the Mayo Clinic. Lifting weights may be even more important when youre cutting back on calories, because your body sheds some muscle mass along with fat when you lose weight. The CDCs weight loss guidelines recommend incorporating strength-training activities that use all the major muscle groups two days a week.

If joint pain makes this kind of exercise challenging, ask your doctor for tips on how to get started safely.

The dietary guidelines from the NPF recommend a reduced-calorie diet for people with psoriatic arthritis who are obese. Talk to your doctor to determine the right goal for you. Tracking your calorie intake can be especially helpful. Studies show that just keeping a simple food journal reduces intake, because it makes you more aware of what youre eating and helps you figure out a better choice, says Prest.A study published in February 2019 in the journal Obesity followed 142 people on their weight loss journey for 24 weeks and found that those who more often used an online food journal reported more weight loss after six months.

I have used the photo journal technique with many clients, and they have had great success in reaching their weight loss goals, says Prest. Free apps and online tracking tools also give you a great estimate of your overall diet, but keep in mind theyre not 100 percent accurate, she adds.

A lack of sleep is linked to impairments in glucose metabolism and an increased risk of type 2 diabetes, metabolic changes, and inflammation, according to a review published in March 2015 in the journal Diabetology and Metabolic Syndrome. This can affect not only your weight loss efforts but also your overall health, including psoriatic arthritis symptoms.

A good nights sleep helps with pain sensitization and improves pain tolerance, and therefore, psoriatic arthritis symptoms might be better, says Bhatt. When the body rests, it rids itself of toxins, which helps improve inflammation. And good sleep helps with weight loss. Davis suggests people with psoriatic arthritis aim for at least 7 to 8 hours of sleep each night.

A study published in October 2018 in the journal Reumatologia suggests that many people who have psoriatic arthritis have trouble sleeping. A few of Bhatts top sleep hygiene tips:

If [youre] struggling, seeing a dietitian is a good idea, says Davis. A dietitian can help you develop a customized meal plan, which can be especially helpful for people who have psoriatic arthritis. People with psoriatic arthritis may find that they have other food sensitivity issues that may contribute to problems with weight loss. Working with a registered dietitian nutritionist is a great way to ensure youre eating the right amount for weight loss, says Prest. You can search for a registered dietitian nutritionist near you at eatright.org.

If youre struggling with exercise, a physical therapist or personal trainer can develop a fitness routine suited to your needs.

Finally, keep at it, because even small changes can be powerful. We often overemphasize pharmaceutical therapies and underemphasize lifestyle changes, says Bhatt, but lifestyle changes are equally important for all arthritis patients.

Link:
Psoriatic Arthritis-Friendly Weight Loss Tips - Everyday Health

Data Bridge Market Research has recently published the Global research Report TitledArthritis Market. The study provides an overview of current statistics and future predictions of the Global Arthritis Market.The study highlights a detailed assessment of the Market and displays market sizing trends by revenue & volume (if applicable), current growth factors, expert opinions, facts, and industry validated market development data.

Global arthritis market is expected to register a substantial CAGR in the forecast period of 2019-2026. The report contains data from the base year of 2018 and the historic year of 2017. This rise in market value can be attributed to the increasing awareness regarding the disease and the modes of its treatment.

Access Insightful Study With Over 100+ Pages, List Of Tables & Figures, Profiling 10+ Companies. Ask For Free Sample Copy Of Arthritis Market Report:https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-arthritis-market&utm_source=&kA

The report gives explanations about market definition, currency and pricing, market segmentation, market overview, premium insights, key insights and company profile of the key market players. With this large scale Arthritis Marketreport, it can also be estimated how the actions of key players are affecting the sales, import, export, revenue and CAGR values. The report also helps analyze the most appropriate method for the distribution of certain products. This market study also estimates the market status, market share, growth rate, sales volume, future trends, market drivers, market restraints, revenue generation, opportunities and challenges, risks and entry barriers, sales channels, and distributors

Top Key Vendors Covered in the report:

AbbVie Inc.; Pfizer Inc.; Amgen Inc.; Johnson & Johnson Services, Inc.; CELGENE CORPORATION; Bristol-Myers Squibb Company; F. Hoffmann-La Roche Ltd; UCB S.A.; Gilead Sciences, Inc.; Eli Lilly and Company; Novartis AG; Sanofi; AstraZeneca; Astellas Pharma Inc.; Galapagos NV; Taisho Pharmaceutical Holdings Co., Ltd.; Boehringer Ingelheim GmbH; Swedish Orphan Biovitrum AB (publ); Regeneron Pharmaceuticals; Abiogen Pharma Spa; Merck & Co., Inc.; Kolon TissueGene, Inc.; Ampio Pharmaceuticals Inc.; GlaxoSmithKline plc among others.

Regions included:

North America (United States, Canada, and Mexico)

Europe (Germany, France, UK, Russia, and Italy)

Asia-Pacific (China, Japan, Korea, India, and Southeast Asia)

South America (Brazil, Argentina, Colombia)

The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, and South Africa)

How Does This Market Insights Help?

Key Pointers Covered in the Arthritis Market Industry Trends and Forecast to 2026

Why choose us:

1. We share precise and exact information about the market forecast;2. Our reports have been examined by professional experts of the industry, which makes them beneficial for the company to maximize their return on investment;3. The analysis acknowledges that the sector players key drivers of both conflicts and Arthritis growth assess the impact of limitations as well as the opportunities on the sector;4. Data regarding Arthritis industry share by every item fragment, alongside their reasonable worth, have been served in the report;5. We provide statistic information, strategic and analysis tool results to provide a sophisticated landscape and target key market players. This will help the company to increase its efficiency;6. Our report helps readers decipher the current and future constraints of the Arthritis market and optimal business strategies to enhance market development;

A complete value chain of the global Arthritis market is presented in the research report. It is associated with the review of the downstream and upstream components of the Arthritis Market. The market is bifurcated on the basis of the categories of products and customer application segments. The market analysis demonstrates the expansion of each segment of the global Arthritis market. The research report assists the user in taking a decisive step that will be a milestone in developing and expanding their businesses in the global Arthritis market.

Get Table Of Contents of This Premium Research For Free: https://www.databridgemarketresearch.com/toc/?dbmr=global-arthritis-market&utm_source=&KA

Major Highlights of TOC covers:

Chapter 1: Methodology & Scope

Chapter 2: Executive Summary

Chapter 3: Arthritis Industry Insights

Chapter 4: Arthritis Market, By Region

Chapter 5: Company Profile

And More..

For More Information or Query or Customization before Buying, Visit at: https://www.databridgemarketresearch.com/inquire-before-buying/?dbmr=global-arthritis-market&utm_source=&KA

Customization of the Report

Data Bridge Market Research also provides customization options to tailor the reports as per client requirements. This report can be personalized to cater to your research needs. Feel free to get in touch with our sales team, who will ensure that you get a report as per your needs.

Thanks for reading this article you can also get individual chapter wise section or region wise report versions like North America, Europe, MEA or Asia Pacific.

About Us:

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with an unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge Market Research provides appropriate solutions to complex business challenges and initiates an effortless decision-making process.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude.We are content with our glorious 99.9 % client satisfying rates

Contact:

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Corporatesales@databridgemarketresearch.com

See the original post:
Arthritis Market Expected to Witness High Growth over the Forecast Period 2019 2026 - Kewaskum Statesman News Journal

ATLANTA, Sept. 14, 2020 (GLOBE NEWSWIRE) -- ATLANTA The American College of Rheumatology (ACR) will hold its first virtual Advocates for Arthritis event on Tuesday, Sept. 15, where more than 120 rheumatologists, rheumatology health professionals, and patient advocates will meet with lawmakers via video to discuss the healthcare challenges they are facing in the midst of COVID-19. During the event, advocates will urge lawmakers to adopt legislation that ensures continued delivery of accessible, safe and affordable care throughout this public health emergency and beyond.

The pandemic has altered almost every aspect of our rheumatology practices, said ACR President Ellen Gravallese, MD. It has impacted our patients lives significantly and required us to create new ways of delivering care through improved telehealth and other adaptations.

Rheumatology providers face significant resource challenges as a result of the current climate. As providers work to balance patient safety and continued access to care, many have been forced to retool their operations, move a significant portion of visits to telehealth, source their own personal protective equipment (PPE), and help patients navigate drug supply challenges while in many cases operating with less staff due to social distancing protocols, furloughs and layoffs.

Meanwhile, patients are concerned about their ability to access rheumatic care while avoiding exposure to the SARS-CoV-2 virus. A recent national patient survey conducted by the ACR found a 52 percent decline since 2019 among patients who say they are currently being treated by a rheumatology provider. Further, 66 percent of respondents reported using telehealth for rheumatology visits, with COVID-19 cited as the most common reason. While telehealth has been a welcome option for providers and patients alike, some visits such as those involving biologic therapy infusions must be conducted in-person via an office visit. Additionally, the rheumatology workforce shortage has made it increasingly difficult for patients in rural areas to find a practicing rheumatologist.

According to the latest federal estimates, 54 million Americans have a doctor-diagnosed rheumatic disease. A recent academic study suggests that number that could be as high as 91 million when taking into account symptoms reported by undiagnosed individuals. Even though as many as one-quarter to one-third of U.S. adults may be living with a rheumatic disease, there is an average of only one practicing rheumatologist for every 40,000 people, while it is estimated that the U.S. will need thousands more adult rheumatologists by 2030 to meet the challenges caused by a rapidly aging population and a fast-retiring workforce.

To address these challenges and ensure the continued delivery of high-quality care, rheumatology providers and patients are encouraging Congressional leaders to adopt the following legislative solutions:

Noting the precarious financial state of cognitive care specialists who treat complex conditions, rheumatology leaders are also urging lawmakers to support the Centers for Medicare & Medicaid Services important updates to the Physician Fee Schedule slated to take effect in January 2021. Established in concert with the American Medical Association, these updated reimbursements for complex office visits also known as Evaluation and Management (E/M) visits are critical to ensuring specialties on the front lines of treating chronic illness can continue serving patients in need.

While the rheumatology community has adapted to meet these challenges head-on, there is serious concern about the long-term sustainability of this new practice landscape without additional, targeted federal interventions and funding support from lawmakers, said Gravallese.

# # #

The American College of Rheumatology (ACR) is an international medical society representing over 7,700 rheumatologists and rheumatology health professionals with a mission to empower rheumatology professionals to excel in their specialty. In doing so, the ACR offers education, research, advocacy and practice management support to help its members continue their innovative work and provide quality patient care. Rheumatologists are experts in the diagnosis, management and treatment of more than 100 different types of arthritis and rheumatic diseases. For more information, visit http://www.rheumatology.org.

Go here to read the rest:
Rheumatology Leaders and Patient Advocates Urge Congress to Address Care Challenges Exacerbated by COVID-19 During the Virtual Advocates for Arthritis...

Global Artificial Cartilage Implant Market: An Overview

Cartilage is a semi-solid dedicated connective tissue. It performs a wide range of roles in the human body. It is designed to bear weight, give support, torsion, and bending, and resists tension. Autologous chondrocyte implantation (ACI) is an advanced cartilage implantation method used in the new formation of the impaired articular cartilage.

Read Report Overview - https://www.transparencymarketresearch.com/artificial-cartilage-implant-market.html

According to the National Joint Registry in the U.K., approximately 160,000 people undergo knee replacement procedures each year. The growing research and developments in relation to synthetic materials, repair procedures, and technologies like 3-D printing are expected to bring major changes to artificial cartilage implant medical procedures in the near future.

The Food and Drug Administration in the U.S. recently granted an approval for synthetic cartilage implants for arthritis. Arthritis is a common ailment among old people. Additionally, the global artificial cartilage implant market is expected to offer treatment for important body parts such as the toe, which bears a major brunt while walking and lifting the body.

Request Brochure of Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=61764

The Transparency Market Research (TMR) report provides an astute analysis of the global artificial cartilage implant market, which includes an in-depth analysis of development indicators and demand parameters that could influence the growth of this market. Main market parameters such as demand drivers and challenges of the global artificial cartilage implant market are discussed at length in this report.

Global Artificial Cartilage Implant Market: Key Trends

Currently, there are over 54.4 million adults in the U.S. who suffer from gout, rheumatoid arthritis, and common arthritis, according to Centers for Disease Control and Prevention. The number is expected to increase rapidly due to growing cases of geriatric ailments. Additionally, ailments like diabetes and lifestyle-related issues such as lack of exercise and fast foods are expected to result in more growth for the artificial cartilage implant market.

Request for Analysis of COVID-19 Impact on Artificial Cartilage Implant Market- https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=61764

Current cartilage implants in the market are not permanent solutions. Additionally, people who undergo surgeries experience immense pain when the connective tissue needs to be replaced. Hence, innovative technologies like durable cartilage implantation are expected to gain a prominent status in the near future. These technologies still in the pipeline of government body approvals replicate both flexibility and strength of the original tissue, and is expected to drive the global artificial cartilage implant market.

The global artificial cartilage implant market also faces some challenges in the near future. The key challenge in the artificial cartilage implant is the high cost of the replacement surgeries. Also stringent regulation procedures by the FDA are also expected hinder the market growth. However, newer synthetic materials which cause fewer complications during surgeries and increase the lifeline of the tissue are expected to drive growth.

Request for Custom Research - https://www.transparencymarketresearch.com/sample/sample.php?flag=CR&rep_id=61764

Global Artificial Cartilage Implant Market: Regional Outlook

Region wise, the upcoming report by TMR can offer insights into the global artificial cartilage implant market in North America, Western Europe, Asia-Pacific, Eastern Europe, Latin America, Middle East and Africa.

The artificial cartilage implant market in North America is expected to bag a notable share of the global artificial cartilage implant market. Large number of knee replacements, increasing geriatric population, and favorable healthcare insurance policies in the U.S. are the driving factors for the markets growth in North America. The artificial cartilage implant market in Asia Pacific is expected to register robust growth. The Asia Pacific market is expected to register significant CAGR growth during the forecast period. Large population, growing number of elderly people, and increasing public and private funding for research and modernization of medical care infrastructure will contribute to the growth of artificial cartilage market in Asia Pacific region.

Pre Book Artificial Cartilage Implant Market Report - https://www.transparencymarketresearch.com/checkout.php?rep_id=61764&ltype=S

Global Artificial Cartilage Implant Market: Competitive Dynamics

A few of the main players in global artificial cartilage implant market are Azellon Cell Therapeutics, Biomet, Inc., DePuy, Anika Therapeutics, and CellGenix.

Browse more Trending Report Transparency Market Research:

Ophthalmic Equipment Market: https://www.transparencymarketresearch.com/ophthalmic-equipment-market.html

Tissue Heart Valves Market: https://www.transparencymarketresearch.com/tissue-heart-valves-market.html

Microarray Scanner Market: https://www.transparencymarketresearch.com/microarray-scanner-market.html

About Us

Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals.

Our reports are single-point solutions for businesses to grow, evolve, and mature. Our real-time data collection methods along with ability to track more than one million high growth niche products are aligned with your aims. The detailed and proprietary statistical models used by our analysts offer insights for making right decision in the shortest span of time. For organizations that require specific but comprehensive information we offer customized solutions through ad hoc reports. These requests are delivered with the perfect combination of right sense of fact-oriented problem solving methodologies and leveraging existing data repositories.

TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.

Contact

Mr. Rohit BhiseyTransparency Market Research

State Tower,

90 State Street,

Suite 700,

Albany NY - 12207

United States

USA - Canada Toll Free: 866-552-3453

Email: sales@transparencymarketresearch.com

Website: https://www.transparencymarketresearch.com/

See more here:
Artificial Cartilage Implant Market: Durable cartilage implantation are expected to gain a prominent status in the near future - BioSpace

Action on rheumatoid arthritis urgent as new data suggest thousands affected constantly experience abuse, stigma and discrimination

A national rheumatoid arthritis (RA) campaign was launched on Monday.We R.A. Prioritygives a voice to the hundreds of thousands of adults of all ages with this often-invisible disease and challenges the potentially damaging misperceptions that persist around the condition.

Findings from new research reinforce the reality of RA in the UK today, with data suggesting many young adults with the condition regularly labelled as having an old persons disease, whilst many continue to face stigma at work and among friends and family.The We R.A. Priority campaign aims to empower those with RA to address perceptions and show how, when RA is treated as a priority, the impact can be life changing, for the individual and for society.

Over 400,000 people across the UK live with RA an incurable, systemic auto-immune condition that can cause intense pain and fatigue to those affected and, if not treated appropriately, can cause irreversible damage to joints and disability.The campaign is calling for urgent change to put a stop to the misperceptions of RA and continued social and economic impact, specifically:

RA needs a unique identity:

differentiated from other arthritic conditions which are not caused by auto-immune dysfunction

Recognition that many symptoms of RA are invisible and debilitating:

so that key audiences such as healthcare professionals, government, employers, venues, transport providers, shops, can take simple steps to better support those affected

Clare Jacklin, Chief Executiveat the National Rheumatoid Arthritis Society (NRAS) said: Over 400,000 people across the UK live with rheumatoid arthritis (RA); yet, in 2020, misunderstanding around the condition is still alarmingly high and is causing deep distress for individuals as well as a major fiscal and social cost to society.

"These are people with incredible potential and to still be in the situation where people are shouted at in the street for using disabled parking spaces because they dont look like they should or they lose their job or overlooked for career progression because of their RA, is simply unacceptable.

"Today the community is calling for urgent action. By taking just simple steps to change attitudes, we can change thousands of lives. Without this, the community could face more challenges as COVID-19 recovery plans establishes other, more recognised conditions as more important. We must act now. The reality is that those affected by RA are capable, and often inspirational people with so much to offer, as long as RA is a priority.

Data collected as part of the campaign captures feedback from over 280 people living with RA insights include:

"These are people with incredible potential and to still be in the situation where people are shouted at in the street for using disabled parking spaces because they dont look like they should or they lose their job or overlooked for career progression because of their RA, is simply unacceptable.

"Today the community is calling for urgent action. By taking just simple steps to change attitudes, we can change thousands of lives. Without this, the community could face more challenges as COVID-19 recovery plans establishes other, more recognised conditions as more important. We must act now. The reality is that those affected by RA are capable, and often inspirational people with so much to offer, as long as RA is a priority.

Data collected as part of the campaign captures feedback from over 280 people living with RA insights include:

93% of people noted that the general public fail to differentiate RA from other forms of arthritis, labelling it an older persons disease - this is despite more than half of all respondents (52%) being diagnosed under the age of 45

85% of people have experienced direct stigma as a result of RA being invisible ranging from accusations of cheating the state benefit system to being called lazy

69% of people have experienced negative attitudes when using disabled facilities as a result of their invisible symptoms with some even receiving verbal abuse

Almost half of people (47%) admitted to not feeling confident to talk to their close friends and family about their condition

One in ten people have lost a job or promotion as a result of their disease:

Previous research has shown that 60% of people with RA stop working more than 5 years earlier than they would have expected to if they had not been diagnosed with RA

More than half of respondents have lied or actively hidden their condition from friends and family, while 80% have pretended to be well enough to socialise in fear of damaging relationships or losing friendships.

Continued here:
Rheumatoid arthritis awareness week launched in the UK | ITV News - ITV News

There is a very low risk of rheumatoid arthritis worsening as a result of changing treatments due to partial or inadequate response, a new study finds. In fact, more than half of such patients treated with adalimumab who had switched to sarilumab experienced clinically meaningful improvements.

These findings were presented at the Clinical Congress of Rheumatology (CCR) East 2020 meeting.

Current guidelines recommend making any necessary therapeutic adjustments if rheumatoid arthritis patients fail to meet treatment goals or remission. Although patients may express health concerns over switching, there have been no data that assesses the association between therapy switching and disease exacerbation.

To fill this gap, a team led by Jeffrey Curtis, MD, MS, MPH, Professor of Medicine at the University of Alabama at Birmingham, performed a post-hoc analysis of the MONARCH Open-Label Extension (OLE) study and evaluated the effects of switching from adalimumab to sarilumab in patients who had partial response to treatment.

Patients who had been randomized to receive 40 mg of adalimumab during the double-blind phase were then transferred to receive 200 mg of sarilumab at the start of the extension study. Those initially receiving sarilumab continued with the regiment during open-label.

The extension study had enrolled a total 320 patients, and 155 ended up switching to the sarilumab group, with 165 maintaining sarilumab treatment.

At OLE baseline, 52% of the population had experienced partial response during the double-blind phase. The investigators noted that, as expected, partial responders were more prominent in the switch group (59%)versus the continuation group (45%).

Furthermore, the continuation group partial responders had similar but numerically lower disease activity scores at OLE baselinewith the exception of tender joint count (TJC) and swollen joint count (SJC).

For the post-hoc analysis, Curtis and team defined partial response as patients with continued moderate-to-high disease activity (Clinical Disease Activity Index [CDAI] > 10) at OLE baseline, regardless of if minimal clinically important difference (MCID) and CDAI had improved following the double-blind phase.

The MCID threshold for patients with high-disease activity at double-blind phase baseline (CDAI<22) was 12 units. The threshold for those with moderate disease activity was 6 units.

After week 24, they noted that only a few partial responders in the switch (6%) and continuation (4%) experienced a worsening of disease activity.

On the contrary, up to 57% of patients in the switch group and 43% in the continuation group experienced improvements in disease activity.

There was no observed change of disease activity in 37% and 53% of the switch and continuation cohorts, respectively.

And finally, the team reported that between OLE baseline and week 24, the mean changes in efficacy parameters and patient reported outcomes had numerically increased. The only exception was SJC28.

A small risk of worsening with the substantial likelihood of meaningful improvement may help alleviate patient fears of worsening when considering a switch to an alternative therapy, such as sarilumab, they concluded.

The study, Low Probability of Clinical Worsening Following Switching Biologic Disease-Modifying Antirheumatic Drug in Patients with Rheumatoid Arthritis and Partial Response to Adalimumab, was presented at CCR East.

Read more:
Switching Antirheumatic Therapies Has Low Risk of Clinical Worsening - MD Magazine

The continuing spread of Coronavirus (COVID-19) amongst major global economies has become an important factor of concern for import and export activities. Learn how companies in the Psoriatic Arthritis Therapeutics market are responding to the Coronavirus crisis by gaining efficacy in alternative strategies that are stabilizing various business activities. Browse through our latest research analysis on COVID-19 and its impact over the global market landscape.

Why Choose Persistence Market Research?

Request Sample Report @ https://www.persistencemarketresearch.co/samples/13729

The report on the global Psoriatic Arthritis Therapeutics market published by Persistence Market Research (PMR) provides a clear understanding of the flight of the Psoriatic Arthritis Therapeutics market over the forecast period (20XX-20XX). The study introspects the various factors that are tipped to influence the growth of the Psoriatic Arthritis Therapeutics market in the upcoming years. The current trends, growth opportunities, restraints, and major challenges faced by market players in the Psoriatic Arthritis Therapeutics market are analyzed in the report.

The study reveals that the global Psoriatic Arthritis Therapeutics market is projected to reach a market value of ~US$XX by the end of 20XX and grow at a CAGR of ~XX% during the assessment period. Further, a qualitative and quantitative analysis of the Psoriatic Arthritis Therapeutics market based on data collected from various credible sources in the market value chain is included in the report along with relevant tables, graphs, and figures.

Relevant Takeaways from Report:

Request Report Methodology @ https://www.persistencemarketresearch.co/methodology/13729

Psoriatic Arthritis Therapeutics Market Segmentation

By Region

The presented study throws light on the current and future prospects of the Psoriatic Arthritis Therapeutics market in various geographies such as:

By Product Type

The report highlights the product adoption pattern of various products in the Psoriatic Arthritis Therapeutics market and provides intricate insights such as the consumption volume,

By End-User

key players and product offerings

For any queries get in touch with Industry Expert @ https://www.persistencemarketresearch.co/ask-an-expert/13729

The report addresses the following doubts related to the Psoriatic Arthritis Therapeutics market:

The rest is here:
Value of Psoriatic Arthritis Therapeutics Market Predicted to Surpass US$ by the of 2017 2025 - The Daily Chronicle

Global Canine Arthritis Treatment Market research report presents a comprehensive overview of market size, share, evolution, trends, and forecast, and growth opportunities of Canine Arthritis Treatment market by product type, application, key manufacturers and key regions and countries. This report offers comprehensive analysis on global Canine Arthritis Treatment market along with, market trends, drivers, and restraints of the Canine Arthritis Treatment market. In-depth study of market size with data Tables, Bar & Pie Charts, and Graphs & Statistics which helps easy to understand detailed breakdown of market.

Note: Our analysts monitoring the situation across the globe explains that the market will generate remunerative prospects for producers post COVID-19 crisis. The report aims to provide an additional illustration of the latest scenario, economic slowdown, and COVID-19 impact on the overall industry.

Get PDF Sample Copy of this Report to understand the structure of the complete report: (Including Full TOC, List of Tables & Figures, Chart) @ https://www.researchmoz.com/enquiry.php?type=S&repid=2685433&source=atm

the following market information:Global Canine Arthritis Treatment Market Size, 2019-2021, and 2020 (quarterly data), (US$ Million)Global Canine Arthritis Treatment Market Size by Type and by Application, 2019-2021, and 2020 (quarterly data), (US$ Million)Global Canine Arthritis Treatment Market Size by Region (and Key Countries), 2019-2021, and 2020 (quarterly data), (US$ Million)Global Canine Arthritis Treatment Market Size by Company, 2019- 2020 (quarterly data), (US$ Million)

Key market playersMajor competitors identified in this market include Elanco (Eli Lilly and Company), Boehringer Ingelheim, Zoetis Inc, Vetoquinol S.A., Bayer AG, Aratana Therapeutics Inc, Norbrook Laboratories Limited, VetStem Biopharma, Dechra Pharmaceuticals Plc, etc.

Based on the Region:Asia-Pacific (China, Japan, South Korea, India and ASEAN)North America (US and Canada)Europe (Germany, France, UK and Italy)Rest of World (Latin America, Middle East & Africa)

Based on the Type:Non-Steroidal Anti-Inflammatory DrugsOpioids

Based on the Application:Veterinary Hospitals and ClinicsDrug StoresE-commerce

Do You Have Any Query Or Specific Requirement? Ask to Our Industry [emailprotected] https://www.researchmoz.com/enquiry.php?type=E&repid=2685433&source=atm

This detailed report on Canine Arthritis Treatment market largely focuses on prominent facets such as product portfolio, payment channels, service offerings, applications, in addition to technological sophistication. The report lends versatile cues on market size and growth traits, besides also offering an in-depth section on opportunity mapping as well as barrier analysis, thus encouraging report readers to incur growth in global Canine Arthritis Treatment market.

This comprehensive research- documentary on global Canine Arthritis Treatment market is a holistic perspective of market developments, factors, dynamics, trends and challenges that decide growth trajectory of global Canine Arthritis Treatment market.

Apart from highlighting these vital realms, the report also includes critical understanding on notable developments and growth estimation across regions at a global context in this report on Canine Arthritis Treatment market.

These leading players are analyzed at length, complete with their product portfolio and company profiles to decipher crucial market findings. Additionally, the competitive landscape of the Canine Arthritis Treatment market is also evaluated at length in the report, to identify and analyze leading service providers.

Geographically, the detailed analysis of consumption, revenue, Canine Arthritis Treatment market share and growth rate, historic and forecast (2015-2026) of the following regions are covered-

North America (USA, Canada and Mexico)

Europe (Germany, France, UK, Russia and Italy)

Asia-Pacific (China, Japan, Korea, India and Southeast Asia)

South America (Brazil, Argentina, Columbia etc.)

Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

All the notable Canine Arthritis Treatment market specific dimensions are studied and analyzed at length in the report to arrive at conclusive insights. Further, a dedicated section on regional overview of the Canine Arthritis Treatment market is also included in the report to identify lucrative growth hubs.

This Canine Arthritis Treatment market also harps on competition intensity, thoroughly identifying and evaluating leading players in the Canine Arthritis Treatment market and their growth stimulators. Besides these aforementioned factors and attributes of the Canine Arthritis Treatment market, this report specifically decodes notable findings and concludes on innumerable factors and growth stimulating decisions that make this Canine Arthritis Treatment market a highly profitable.

You can Buy This Report from Here @ https://www.researchmoz.com/checkout?rep_id=2685433&licType=S&source=atm

A thorough take on essential elements such as drivers, threats, challenges, opportunities are thoroughly assessed and analyzed to arrive at logical conclusions. As the report proceeds further, Even further in the report emphasis has been lent on current, historical, as well as future growth tendencies to make accurate growth estimations based on market size, value, volume, demand and supply trends as well as growth rate.

Other vital factors related to the Canine Arthritis Treatment market such as scope, growth potential, profitability, and structural break-down have been innately roped in this Canine Arthritis Treatment report to accelerate market growth. This research compilation on Canine Arthritis Treatment market is a meticulous compilation of in-depth primary and secondary research. The report also lists ample understanding on various analytical practices such as SWOT and PESTEL analysis to guide optimum profits in Canine Arthritis Treatment market. The report is a conscious attempt to unearth market specific developments to ignite growth specific market discretion.

For More Information Kindly Contact:

ResearchMoz

Mr. Rohit Bhisey,

90 State Street,

Albany NY,

United States 12207

Tel: +1-518-621-2074

USA-Canada Toll Free: 866-997-4948

Email: [emailprotected]

Follow this link:
Canine Arthritis Treatment Market : Facts, Figures and Analytical Insights, 2019 to 2025 - The Daily Chronicle

DUBLIN--(BUSINESS WIRE)--The "Rheumatoid Arthritis (RA) - Epidemiology Forecast to 2030" report has been added to ResearchAndMarkets.com's offering.

This report delivers an in-depth understanding of the disease, historical and forecasted RA epidemiology in the 7MM, i.e., the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Rheumatoid Arthritis (RA) Understanding

Rheumatoid Arthritis Overview

Rheumatoid arthritis (RA) is an autoimmune or chronic inflammatory disease that is known to impact the joints of the body adversely. An autoimmune disorder is a condition where the immune system starts making antinuclear bodies instead of antibodies which directs them to cause self-injury to the body, on the onset of disease, the immune response primarily attacks and harm the joints. RA is more common in women and about 75% of RA patients are women. Around 1 to 3% of women may get rheumatoid arthritis in their lifetime. The disease most often begins between the ages of 30 and 50. However, RA can start at any age.

Clinically, the symptoms of RA significantly differ between early-stage RA and insufficiently treated later stages of the disease. Early-stage RA is characterized by generalized disease symptoms such as fatigue, flu-like feeling, swollen and tender joints, and morning stiffness; and is paralleled by elevated levels of C-reactive protein (CRP) and an increased erythrocyte sedimentation rate (ESR). In contrast, insufficiently treated RA displays a complex clinical picture with the occurrence of serious systemic manifestations such as pleural effusions, lung nodules and interstitial lung disease, lymphomas, vasculitis in small or medium-sized arteries, keratoconjunctivitis, atherosclerosis, hematologic abnormalities (e.g., anemia, leukopenia, neutropenia, eosinophilia, thrombocytopenia, or thrombocytosis), joint misalignments, loss of range of motion, bone erosion, cartilage destruction, and rheumatic nodules. These systemic manifestations caused by the chronic inflammatory state in RA patients result in increased mortality.

Rheumatoid Arthritis Diagnosis

Typically, RA is diagnosed by a combination of patient's symptoms, results of doctors examination, assessment of risk factors, family history, a joint assessment by ultrasound sonography, and assessment of laboratory markers such as elevated levels of CRP and ESR in serum and detection of RA-specific autoantibodies.

More than two thirds of RA patients have reported moderate to severe symptoms and having disease activity (DAS) score of 3.2 or above. And by this stage, most of the patients have joints that are experiencing swelling and pain and may have deformities, like malalignment, in some joints as a result of cartilage destruction.

Epidemiology Perspective

The RA epidemiology division provides the insights about historical and current RA patient pool and forecasted trend for each seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

In the year 2017, the total prevalent cases of RA was 4,356,793 cases in the 7MM which are expected to grow during the study period, i.e., 2017-2030.

The disease epidemiology covered in the report provides historical as well as forecasted RA epidemiology segmented as [Total Prevalent Cases of RA, Diagnosed cases of RA, Gender-specific cases of RA, Diagnosed cases of RA by Age Distribution, Severity-specific cases of RA, Patients on targeted therapies of RA, and Line-Wise Treated Cases of RA] scenario of RA in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2017 to 2030.

Country Wise- RA Epidemiology

Estimates show that the highest cases of RA in the 7MM were in the United States, followed by Japan, Germany, the United Kingdom, France, Italy, and Spain in 2017.

Reasons to buy

Key Assessments

Geographies Covered

Study Period: 2017-2030

For more information about this report visit https://www.researchandmarkets.com/r/fxpicl

Read the original:
Insights into the Rheumatoid Arthritis Industry to 2030 - Develop Business Strategies by Understanding Trends - ResearchAndMarkets.com - Business Wire

Most adults with systemic lupus erythematosus (SLE) are not at increased risk of hospitalization from 2019 coronavirus disease (COVID-19) due to medications used to dampen their altered immune system, the cause of the disease. Nor are most people with more common types of arthritis, such as rheumatoid, psoriatic, and spondyloarthritis, at greater risk of hospitalization from COVID-19, a pair of new reports shows.

SLE, known widely as lupus, along with common forms of arthritis are autoimmune conditions caused by the immune systems mistaken attack on a persons own tissues, leading to inflammation in the joints, skin, kidneys, and other parts of the body. The majority of those affected by these diseases are women.

Although the new studies, led by NYU Grossman School of Medicine researchers, show that for some of those affected the use of steroid medications to reduce inflammation slightly increased the likelihood of needing hospital care, researchers say the results should be reassuring to patients overall.

Many people are taking steroids or other immunosuppressing medications, especially newer biologic drugs, to prevent their immune systems attack on their tissues. And the researchers say their patients report feeling added anxiety that their treatments make them more susceptible to the dangers of coronavirus infection.

In the first study, published recently in the journal Arthritis and Rheumatology, researchers closely monitored the health of 226 adult patients, mostly Black, Hispanic, and female, receiving treatment at NYU Langone Health clinics or NYC Health + Hospitals/Bellevue for mild to severe forms of lupus. All were surveyed by phone or email, or had their medical records checked between April 13 and June 1, when the pandemic peaked in the New York City region. Twenty-four were hospitalized out of 41 who were formally diagnosed with COVID-19, and 4 of them died. Another 42 had COVID-19like symptoms but were not formally tested.

For the second study, also published in Arthritis and Rheumatology, researchers monitored 103 mostly white women being treated at NYU Langone Health clinics between March 3 and May 4 for inflammatory arthritis, which unlike common osteoarthritis, does not primarily result from joint wear and tear. All tested positive for COVID-19 or had symptoms highly suggesting they were infected. Twenty-seven (26 percent) were hospitalized, with 4 deaths (4 percent).

Researchers say their latest study findings showed that patients with lupus taking immune-suppressing medications, such as mycophenolate mofetil (CellCept) and azathioprine (Imuran), had no greater risk of hospitalization (15 out of 24) than patients with lupus not using the medications (9 of 17). Similarly, hospitalization rates for people with inflammatory arthritis (26 percent) and COVID-19 were also no greater than seen for all New Yorkers (25 percent, according to city figures).

Among the research teams other findings was that patients taking biologic drugs for arthritis, such as adalimumab (Humira) and etanercept (Enbrel), which are made from living cells, or the antiviral hydroxychloroquine, were at no greater or lesser risk of hospitalization than those not taking the drugs. However, those taking glucocorticoids, a type of steroid, even in mild doses, were upwards of 10 times more likely to be hospitalized than patients with arthritis not using steroids. The researchers caution that although statistically significant, the studys small size may overestimate the actual risk.

Our findings represent the largest of its kind for American patients with lupus or arthritis and COVID-19, and should reassure most patients, especially those on immunosuppressant therapy, that they are at no greater risk of having to be admitted to hospital from COVID-19 than other lupus or arthritis patients, says one of the studies co-lead investigators, Ruth Fernandez-Ruiz, MD.

People with lupus or inflammatory arthritis have the same risk factors for getting seriously ill from COVID-19 as people without these disorders, says Dr. Fernandez-Ruiz, a postdoctoral fellow in rheumatology in the Department of Medicine at NYU Langone.

These shared risk factors, she says, which overall more than double peoples risk of hospitalization from COVID-19, are having multiple underlying health conditions, such as obesity, hypertension, and diabetes.

Patients receiving therapy for lupus and inflammatory arthritis should not automatically stop taking their medications for fear that they would be worse off if they also caught the coronavirus, says another of the studies co-lead investigators, Rebecca Haberman, MD. Instead, rheumatology patients should consult with their medical provider about their overall risk factors for COVID-19 and make plans accordingly, says Dr. Haberman, a clinical instructor in rheumatology in the Department of Medicine at NYU Langone.

Dr. Fernandez-Ruiz says the team now plans to test patients with lupus and patients with arthritis for coronavirus antibodies to see how many study participants were infected at some point and whether any were at greater or lesser risk of infection.

Funding support for the studies was provided by National Institutes of Health grants P50 AR07059, R01 AR074500, and T32 AR069515. Additional support was provided by Bloomberg Philanthropies COVID-19 Response Initiative Grants, The Riley Family Foundation, The Snyder Family Foundation, and Pfizers COVID-19 Competitive Grants Program.

Dr. Haberman and other study investigators have participated in other research projects sponsored by various manufacturers of arthritis drugs, as well as served on advisory boards to AbbVie, Amgen, Astrazeneca, Bristol-Myers Squibb, Celgene, Corrona, Eli Lilly, GlaxoSmithKline, Janssen, Johnson & Johnson, Novartis, Pfizer, Sanofi, and UCB. All of these arrangements are being managed in accordance with the policies and practices of NYU Langone.

Besides Dr. Haberman and Dr. Fernandez-Ruiz, other NYU Langone researchers involved in the studies are co-lead investigators Mala Masson, Rochelle L. Castillo, MD, and Alan Chen; senior investigators Amit Saxena, MD, Peter M. Izmirly, MD, Samrachana Adhikari, PhD, and Jose U. Scher, MD; and co-investigators Allison Guttman, Philip Carlucci, Kristina Deonaraine, Michael Golpanian, Kimberly Robins, Miao Chang, H. Michael Belmont, MD, Jill P. Buyon, MD, Ashira Blazer, MD, Di Yan, and Deborah Ramirez. Additional study co-investigators are Mimi Kim at Albert Einstein College of Medicine in New York; and Benjamin Myers at Cornell University in Ithaca, New York.

David MarchPhone: 212-404-3528david.march@nyulangone.org

Read the rest here:
Most Adults with Lupus or Common Types of Arthritis Have Similar Risks of Getting Admitted to Hospital as Other Patients with COVID-19 - NYU Langone...

Disease-modifying antirheumatic drugs have reduced the need for total knee and hip arthroplasties (TKA and THA) in patients with rheumatoid arthritis (RA). However, there is still a far greater long-term risk of undergoing THA or TKA in patients with RA compared with patients who do not have RA, according to a study published in The Journal of Arthroplasty.

Since 1991 the proportion of patients with RA who are required to undergo TKA has dropped from 21.0% to as low as 2.4%. However, the few previous studies have been based on populations in the United States and Europe.

Patients with RA who experience joint destruction, intractable joint pain, or unacceptable functional decline usually require joint arthroplasty, the authors explained.

Researchers conducted a large-scale retrospective cohort study of 32,949 patients in Taiwan who were diagnosed with RA from 2000 to 2012. They were matched with 32,949 non-RA controls. Patients with RA had a more unfavorable Charlson comorbidity index score.

After adjusting for demographics and comorbidities, patients in the RA cohort had a 4.02-fold higher risk of undergoing TKA or THA (95% CI, 3.67-4.41). Factors that significantly increased the risk of THA or TKA were increasing age, living in an area of low urbanization, working as a manual laborer, 1 point in CCI score, having hypertension, or having gout.

Using multivariable stratified analyses, the researchers found that patients younger than 40 years actually had the highest risk of THA or TKA (adjusted hazard ratio, 43.18; 95% CI, 16.01-116.47). Careful interpretation of the results is needed because of relatively small sample size of this age interval, the authors noted.

However, they did note a previous study had shown young-onset RA was correlated with reduced radiographic progression and better functional score after 3 years. Those findings taken with the findings from the current study suggest that despite the better short-term outcome, patients with young-onset RA are still more at risk of undergoing TKA and THA compared with patients with late-onset RA, the authors wrote.

Based on the actual surgical procedures performed, patients with RA had a 4.56-fold higher risk of requiring THA, a 3.85-fold higher risk of TKA, and a 19.39-fold higher risk of requiring both THA and TKA compared with the non-RA cohort.

We recommend that future researchers can include more detailed documented dose or regimen of DMARDs utilization to verify the doseresponse effect in reducing the THA or TKA in RA patients, the authors concluded.

Reference

Lee Y-H, Ko P-Y, Kao S-L, Lin M-C, Cheng-Chung Wei J. Risk of total knee and hip arthroplasty in patients with rheumatoid arthritis: a 12-year retrospective cohort study of 65,898 patients. J Arthroplasty. Published online July 2, 2020. doi:10.1016/j.arth.2020.06.085

Go here to read the rest:
Understanding the Risk of Joint Replacement in Patients With Rheumatoid Arthritis - AJMC.com Managed Markets Network